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Abstract   
Background/Aims: Despite being amphetamine derivatives, MDMA and its analogues show 
a number of clinical pharmacological differences with respect to both amphetamine (AMP) 
and methylamphetamine (METH). We aimed here at reporting and analysing information 
relating to the socio-demographics and clinical circumstances of the amphetamine-type 
stimulant related deaths for the whole of the UK.   
Methods: Data (1997-2007) were taken from the National Programme on Substance Abuse 
Deaths (np-SAD) database, collecting information from UK Coroners/procurators fiscal. To 
calculate rates of fatalities per 100,000 users, appropriate AMP/METH and ecstasy users’ 
numbers were taken from the 2001-2007 British Crime Survey. 
Results: Overall, 832 AMP/METH- and 605 ecstasy- (mostly MDMA and 
methylenedioxyamphetamine/MDA) related deaths were respectively identified. In 
comparison with AMP/METH victims, the ecstasy ones were more likely to be: younger 
(28.3 vs 32.7 years; p< .0001) and less likely to be known as drug users (PR=1.9; CI: 1.5-
2.6). Ecstasy was more likely to be identified on its own than AMP/METH (p=0.0192). 
Contributory factors were more frequently mentioned by Coroners in the ‘AMP/METH only’ 
(106 cases) group than in the ‘ecstasy only’ (104 cases) one (p=0.0043). Both poly-drug and 
mono-drug AMP/METH fatalities per 100,000 16-59 year old users were significantly more 
represented than ecstasy fatalities (respectively: 17.87 +/- 4.77 deaths vs 10.89+/-1.27; 
p=0.000; 2.09 +/- 0.88 vs 1.75 +/- 0.56; p=0.0096). However, mono-intoxication ecstasy 
fatalities per 100,000 16-24 years old users were significantly more represented than 
AMP/METH fatalities (1.67 +/- 0.52 vs 0.8+/- 0.65; p=0.0007). 
Conclusion: With respect to AMP/METH, ecstasy was here more typically identified in 
victims who were young, healthy, and less likely to be known as drug users. AMP/METH 
high mortality rates may be explained by users’ high levels of physical co-morbidity; excess 
ecstasy-related fatality rates in young users may be a reason of concern. Although the 
Coroners’ response rate was of 90-95%, study limitations include both reporting 
inconsistency over time and lack of routine information on drug intake levels prior to death.  
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Introduction 
In the second part of the ’90s, a global trend of escalating amphetamine-type stimulant (ATS; 
a group including amphetamine, methylamphetamine, ecstasy and the ecstasy-type drugs) use 
was observed [1]. Despite being amphetamine derivatives, MDMA and MDMA-like drugs 
clearly show a number of clinical pharmacological differences with respect to both 
amphetamine and methylamphetamine. MDMA and other phenethylamine  drugs (including: 
methylenedioxyamphetamine/ MDA/‘love drug’; 
methylenedioxyethylamphetamine/MDEA/’eve’, paramethoxyamphetamine/PMA; and –
methylthioamphetamine/4-MTA/’flatliners’) occupy an intermediate position between 
stimulants and hallucinogens, making up the distinct class of ‘entactogens’ [2]. In contrast 
with amphetamine and its immediate derivatives, which can be prescribed for a number of 
clinical conditions [3], MDMA/ecstasy and the remaining entactogens do not have any 
recognized therapeutic use so far. 
 
The risk of ecstasy ‘overdose’ has been described in the UK since the early 1990s [4]; ecstasy 
price fluctuations over the years are inversely correlated with levels of ecstasy availability 
and numbers of related deaths [5]. In England and Wales, in parallel with increased 
surveillance, a steady and constant increase of ecstasy-related fatalities has been observed in 
the time frame August 1996–April 2002, when a total of 202 related deaths were recorded 
[6]. It is of concern that significant number of ecstasy related deaths occur at doses associated 
with recreational use [4]; both individual drug polymorphysms and polydrug abuse ingestion 
itself may act as confounding factors [7]. It seems that not all entactogens show similar 
overdose risks. In fact, although MDA, MDEA and MBDB show acute toxicity levels 
comparable to MDMA [5], PMA has been associated with a much higher rate of lethal 
complications than MDMA [8, 9]. Similarly, Carmo et al [10] suggested that 4-MTA in 
humans has been associated with severe intoxications and several deaths.   
 
Data related to amphetamine/methylamphetamine (AMP/METH) deaths in the UK (1990-
2002) have previously been commented on as well [11], but no studies have described so far 
the possible similarities and differences between the AMP/METH-related and the entactogen-
related fatalities.  
 
Given the very large numbers of consumers involved in the use of amphetamine-type 
stimulants across both the EU and the UK [12], the main aims of this study were to report and 
analyse information relating to the socio-demographics and clinical circumstances of all 
recorded ATS-related deaths for the whole of the UK, both when the index drugs were taken 
on their own and when in combination with other drugs.  To provide a better understanding 
of the relative toxicity risk of AMP/METH and MDMA/ecstasy, rates of related deaths over 
the years were also assessed whenever possible whilst taking into account number of 
consumers of AMP/METH and MDMA/ecstasy, respectively.  
 
Methods  
Established in 1997, the National Programme on Substance Abuse Deaths (np-SAD) [13] 
collects all information pertaining to drug related deaths from the UK Coroners’ and 
procurators' fiscal jurisdictions, as well as data collated by the Scottish Crime & Drug 
Enforcement Agency from Scottish police forces. An np-SAD case is defined as a relevant 
death where any of the following criteria are met at a completed inquest, fatal accident 
inquiry or similar investigation: a) one or more psychoactive substances directly implicated in 
death; b) history of dependence or abuse of psychoactive drugs; c) presence of controlled 
drugs at post mortem; or d) cases of deaths directly due to drugs but with no inquest. More 
specifically, np-SAD database deaths here included were those in which one or more ATS 
drugs were either directly implicated in death and/or were identified during necropsy.  
 The response rate from Coroners in England and Wales is typically in the region of 90-95% 
[13]. In line with Schifano et al [5], we defined here deaths related to ecstasy as a Coroner's 
report including ‘ecstasy,’ ‘XTC ’, ‘MDMA’, ‘MDA’, ‘MBDB’, and ‘MDEA’. Although 
presenting with different toxicity levels [10, 9], we tried to identify here as well possible 
mentions of ‘PMA’ and ‘4-MTA’, since Coroners may at times include these entactogens in 
the broader ‘ecstasy-type’ group. Conversely, deaths identified as amphetamine/ 
methylamphetamine (AMP/METH) included the text ‘amphetamine’, ‘methylamphetamine’, 
‘methamphetamine’ and ‘amphetamine salts’. Data shown here refer to analysis of the whole 
of the np-SAD database, from 1 July 1997 to 15 April 15 2009. In this way, the range of data 
extends from 1997 to 2007. In fact, it is argued here that by mid-April 2009 the vast majority 
of Coroners’ inquests related to deaths occurring in 2007 were already completed and 
included in the database. Mono-substance deaths were defined as the index drug was found at 
post mortem on its own or the index drug was the sole drug implicated and there was no other 
substance found at post mortem.     
 
Apart from the raw number of ATS-related fatalities observed over the years, to better 
interpret the available data number of AMP/METH and MDMA/ecstasy fatalities will be 
respectively analyzed whilst taking into account both the total number of substance-related 
deaths reported to np-SAD and the total number of the index ATS consumers as 
denominators. In particular, to calculate number of AMP/METH and MDMA/ecstasy 
consumers over the years, data from the British Crime Survey (BCS; England and Wales) 
were taken into account. The BCS offers regular estimates of last year use for amphetamines 
and ecstasy, although this is only available from 2001 onwards [14 – 20]. 
 
Descriptive statistics were used for data sources; probability ratios (PR) and 95% confidence 
intervals (95% CI) were reported. The Mann-Whitney U test was used to calculate age 
differences in the two groups and the chi square test to analyse categorical variables. Rates of 
deaths per 100,000 users were calculated using BCS for last year use and np-SAD cases 
reported by coroners in England and Wales for the relevant age groups. The data were 
analysed using SPSS™ for Windows version 15.  
  
Results 
Figure 1 shows the rates of AMP/METH and ecstasy-related deaths reported to the np-SAD 
over the years. The number of AMP/METH deaths peaked first in 1998, fell steeply in 2000 
but since then have increased to a higher peak in 2007; rates of ecstasy fatalities peaked first 
in 2001 and fell slightly afterwards before rising to a new peak in 2006.  
 
Insert figure 1 around here  
 
Overall, 832 AMP/METH- and 605 ecstasy-related deaths were respectively identified (see 
table 1). In the so called ‘ecstasy’ group, during the study period 1997-2007 the following 
drugs were mentioned at post mortem: MDMA 564; MDA 117; MDEA 4; PMA 1 (in a 
number of cases, more than one entactogenic drug was identified). 
 
With respect to the AMP/METH polydrug victims (see table 1), the ecstasy polydrug ones 
were more likely to be younger (28.3 vs 32.7 years; p< .0001) and less likely to be known as 
drug addicts/users (PR=1.9; CI: 1.5-2.6). In the polydrug cases (see table 1), both alcohol 
(PR=1.5; CI: 1.3-1.8) and cocaine (PR=1.8; CI: 1.4-2.2) were more frequently identified in 
the ecstasy group, whilst both methadone (PR=1.9; CI: 1.4-2.5), heroin/morphine (PR=1.6; 
CI: 1.3-1.8), and other opiates/opioid analgesics (PR=1.4; CI:1.0-1.9) were more likely to be 
reported in the AMP/METH group.  
 
Although most AMP/METH and ecstasy victims died of polydrug abuse ingestion, ecstasy 
was more likely to be identified on its own (104 cases out of 605) than AMP/METH (106 
cases out of 832; Fisher's exact test; two-tailed P value= 0.0192; see table 2). In these mono-
intoxication groups, the index ATS drug was either the sole drug found at post mortem or the 
sole drug implicated and no other substances were identified at post mortem.  Similarly to 
what was identified in comparing multiple drug misuse fatalities, in comparison with the 
AMP/METH only victims the ‘ecstasy only’ ones turned out to be younger (23.9 vs 32.0 
years; p< .0001) and less likely to be known as drug addicts/users (PR=2.8; CI: 1.5-5.5). 
Furthermore, suicide trended towards significance in ecstasy only-related deaths (PR=1.5; CI: 
0.4-5.3; see table 2).  
 
Insert tables 1 and 2 around here 
 
In the ‘ecstasy only’ group, no contributory factors/suicidal intent were identified in 90 out of 
104 (86.5%) cases, with only ecstasy and its well-known acute medical consequences 
(Schifano, 2004) having been mentioned as the cause of death (see table 3). Conversely, the 
presence of contributory factors (74 cases out of 106 cases; 69.8%) was more frequently 
mentioned by Coroners in the group of ‘AMP/METH only’ fatalities (Fisher's exact test; two-
tailed p=0.0043). Similarly (see table 3), the proportion of deaths directly attributed to 
toxicity related to the index ATS drugs out of the total number of fatalities in which the index 
drug (either on its own or in combination) was implicated in death was found to be higher for 
the ecstasy only group with respect to the AMP/METH only group (90/605 vs 74/832; 
Fisher's exact test; two-tailed p=0.0005). 
 
Insert table 3 around here  
 
For the examination of ATS fatalities within the larger context of drug related fatalities, we 
calculated rates of deaths for the index drugs compared to all deaths reported to np-SAD over 
the study period (1997-2007). It appeared (see both table 4 and figure 2) that although average 
rates of ‘AMP/METH only’ (0.58%) over the years were comparable to the ‘ecstasy only’ 
ones (0.57%), AMP/METH polydrug intoxication fatalities (average value over the years: 
4.53%; range: 3.02-6.23%) were more frequently identified than the ecstasy polydrug 
intoxication ones (average value over the years: 3.29%; range: 1.14-4.32%) 
 
Insert both table 4 and figure 2 around here  
 
In terms of rates of deaths per 100,000 users of AMP/METH and ecstasy (2001-2007 only), if 
data related to multiple drug intoxication were taken into account (see table 5) it appeared 
that AMP/METH fatalities were significantly more represented (17.87 +/- 4.77 deaths vs 
10.89+/-1.27; p=0.000) than ecstasy fatalities if the whole of the population (16-59 years old; 
see figure 3) of users was taken into account. Conversely, if only data related to mono-
intoxication fatalities were taken into account (see table 6), it appeared that rates of 16-24 
years old (see figure 4) ecstasy fatalities per 100,000 16-24 years old users were significantly 
more represented than 16-24 years old AMP/METH fatalities per 100,000 16-24 years old 
users (1.67 +/- 0.52 vs 0.8+/- 0.65; p=0.0007). Conversely, ‘AMP/METH only’ fatalities per 
100,000 users were more represented than ecstasy fatalities if all ages were taken into 
account (2.09 +/- 0.88 vs 1.75 +/- 0.56; p=0.0096; see table 6). 
 
Insert tables 5 and 6 and figures 3 and 4 around here 
 
Discussion 
This report has provided an 11-year, UK-wide, analysis of ecstasy/entactogen (MDMA, 
MDA, MDEA, MBDB, PMA) and amphetamine/methylamphetamine mortality data set. This 
may constitute the largest collection of amphetamine-type stimulant fatalities so far, offering 
both detailed notes of the individual clinical/accidental circumstances contributing to death 
and direct comparison of data referring to ecstasy on one hand and AMP/METH on the other.  
 
It is interesting to note that number of AMP/METH deaths seemed to have dropped in 2000 
to peak once again over the few following years and that rates of MDMA-related fatalities 
after a drop in 2003 increased over the following few years. Although data to offer a 
straightforward explanation for this year-on-year change are not available from this data-
source, it is intriguing that previous observations have suggested similarly increasing rates of 
other stimulant- (e.g. cocaine/crack cocaine) related deaths in the UK after 2001-2002 [21].  
On the other hand, ATS percent deaths did not show here a substantial and consistent 
increase over the years. Since ATS fatality figures have indeed increased during the index 
period, one could wonder if this increase in ATS-related deaths may just be reflecting a more 
generalized increase in all drug-related deaths over the years. However, recent data may 
suggest a stabilization instead of an increase in UK drug related deaths during the period 
1998-2008 [22]. Of course, changes in fatality rates over time may be related to parallel 
changes in coroner methods/policies/laws/technology, which would in turn affect 
surveillance. 
 
Typical ATS victims in this study were young, males (thus confirming previous reports) [23] 
and white. In comparison with amphetamine, ecstasy seemed here to be both more likely to 
be identified on its own at post mortem and less likely to be associated with 
concomitant/contributory factors when taken on its own.  
 
Indeed, most AMP/METH and ecstasy victims died of polydrug abuse ingestion. Ecstasy 
fatal ingestion seemed here to be most typically identified together with cocaine, and both 
drugs are frequently associated with the recreational scene [24]. This is consistent with the 
observation made here that, with respect to the AMP/METH victims, the ecstasy ones were 
more likely to be without a known history of drug addiction. Co-occurrence of two stimulants 
(i.e.: MDMA together with cocaine) might increase, in a synergic way, both the 
dopaminergic and serotonergic stimulation, so that the serotonin syndrome is more likely to 
occur [7]. Ecstasy was here identified on its own at post mortem in about 1 case out of 6; 
according to the UK General Mortality Registers (GMRs) figures, ecstasy was the sole drug 
mentioned in the death certificate in 42% of the total number of related fatalities [5]. The 
reason for the discrepancy between the np-SAD and the GMRs data may be due to the fact 
that the np-SAD data capture system allows collection of fairly detailed information from 
Coroners. As a consequence, a more precise description of the index related death is made 
possible and this may have decreased, in the present np-SAD dataset, the number of cases in 
which ecstasy was considered to be involved on its own. 
  
Contributory clinical factors here described at post mortem in ATS fatalities were overall 
consistent with the existing, mainly anecdotal in nature, literature and reflect a number of 
issues, including: the sympathomimetic actions of both AMP/METH and ecstasy [25, 26]; the 
possible idiosyncratic toxic reactions to these compounds [4]; and the accident-proneness 
behaviour of ATS misusers [4, 27, 28]. The sympathomimetic stimulation may be further 
exacerbated by the environmental condition which is in turn induced by both the repetitive 
high frequency rhythm of the techno music itself and by the aggregation in close 
environments/high ambient temperature [26]. 
  
Different from ecstasy, AMP/METH drugs were here frequently identified in combination 
with heroin, methadone, and other opiates/opioid analgesics which are all drugs with high 
levels of toxicity in overdose and typically associated with the ‘hard core’ addiction scene 
[13]. Present data suggested that, within the AMP/METH only fatalities’ group, a sizeable 
proportion of fatalities occurred in a context of physical, and especially cardiovascular, 
disorders. In amphetamine misusers, deaths are typically associated with acute myocardial 
necrosis, right ventricle rupture, cardiomyopathy, arrhythmia [29], polytrauma, mechanical 
asphyxia, and hyperthermia [23]. Conversely, suicide was more likely to be identified here as 
a cause of death in the ecstasy than in the AMP/METH group. From this point of view, some 
longitudinal research has been dedicated to the understanding of the association between 
ecstasy intake and depression [30].  
 
Overall, the present results seem to suggest that proportion of AMP/METH polydrug 
intoxication fatalities out of all deaths reported to np-SAD were over the years consistently 
higher than the ecstasy polydrug intoxication ones. This result is likely, however, to be in 
relation to higher number of consumers of AMP/METH than ecstasy in the UK [12]. In terms 
of death rates per 100,000 (16-59 years old) users of AMP/METH and ecstasy (2001-2007 
only), it appeared that both mono- and poly-drug AMP/METH fatalities were significantly 
more represented than ecstasy fatalities. However, compared to ecstasy users AMP/METH 
users were here more likely to be: using opiates/opioids (which are frequently self-
administered intravenously and associated with increased inherent risk of lethal accidental 
overdose); known drug abusers with the related poor living standards; and reporting 
associated chronic medical co-morbidities. On the other hand, it seems interesting to note that 
if only the 16-24 years old population was taken into account rates of ecstasy fatalities per 
100,000 users were significantly higher than AMP/METH fatalities. This may be partly 
explained by the fact that the physical co-morbidities linked to both AMP/METH and its 
related at-risk lifestyle still had to show an impact on the user given the young age/ 
conceivably relatively short period of use. A further explanation might however be given by 
the particular susceptibility of youngster to the acute effects of ecstasy [7].  Finally, one could 
wonder if differences between ecstasy and AMP/METH rates in youngsters may be related to 
BCS reporting bias. However, although the survey may in fact tend to over-represent older 
age groups at the expense of younger respondents, BCS may be prone to sampling error only 
where rare crimes are concerned [31].  
 
The present paper presents with some limitations. In fact, although the np-SAD coverage is 
excellent (about 90-95%) [22], levels of reporting inconsistency between the different areas 
have been recorded over time. Furthermore, Coroners’ reports do not routinely include either 
information on levels of drug intake prior to death or post mortem toxicological levels. One 
could wonder what kind of cases the coronial system would miss. Typically, coroners enquire 
only into those fatalities reported to them, which include deaths which were sudden, 
unexpected, violent or unnatural. Indeed, not all deaths are reported to the coroner and in 
most cases a GP or hospital doctor can issue a medical certificate of the cause of death. From 
this point of view, one cannot exclude that some people who died due to ATSs, maybe whilst 
in hospital for a concurrent medical disease, were not identified by coroners. At present, the 
np-SAD Programme aims at establishing if all relevant cases are being identified and notified 
by the coronial system. Finally, the np-SAD has been giving consideration as to how it can 
further improve both the quality of information collected by coroners, which already include 
reference to the deceased medical and psychiatric history; comorbid conditions; and history 
of drug use.  
 
Conclusions  
With respect to AMP/METH, ecstasy was here more typically identified in victims who were 
young, healthy, and less likely to be known as drug users. Although AMP/METH high 
mortality rates here observed may be explained by users’ high levels of physical co-
morbidity, excess ecstasy-related fatality rates in young users may be a reason of concern.  
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Table 1: Overview of amphetamine/methylamphetamine - and ecstasy-associated 
fatalities as reported to the National Programme on Substance Abuse Deaths - np-SAD 
(UK: 1997-2007) 
 Amphetamine/methylamphetamine 
(*)  
Ecstasy (**) PR/significance 
levels 
95% CI 
No of reported 
deaths (1997-
2007)  
832 605 
 
 
Male gender  80.2%  85.0%  1.1  1.0-1.1  
Less than 34 
years at death 
60.9% 79.5% 1.6 1.5-1.8 
Age at death 
(years)  
mean  
median  
Semi-interquartile 
range  
32.7  
31.9  
6.7 
28.3  
27.0  
5.5 
Mann-Whitney  
U test= 179664,  
p <.0001 (2-
tailed) 
 
Died in hospital  31.3%  39.2%  1.2  1.1-1.4  
Known drug 
addiction   
91.7%  82.1%  1.9  1.5-2.6  
Cause of death; 
accidental  
71.9%  72.2%  1.0  0.9-1.1  
Cause of death; 
suicide  
3.1%  4.1%  1.3  0.8-2.3  
Index drug on its 
own  
12.7% (106/832 deaths where  
amphetamine was identified on its 
own)  
17.2% 
(104/605 
deaths where  
ecstasy was 
identified on 
its own)  
Fisher's exact test;  
two-tailed P 
value=  0.0192 
 
Other drugs 
implicated; 
alcohol  
20.4%  31.6%  1.5  1.3-1.8  
Other drugs 
implicated;  
 cocaine  
12.6%  22.3%  1.8  1.4-2.2  
Other drugs 
implicated; 
heroin/morphine  
39.3%  25.3%  1.6  1.3-1.8  
Other drugs 
implicated; 
methadone  
17.4%  9.3%  1.9  1.4-2.5  
Other drugs 
implicated; other 
opiates/ opioid 
analgesics 
13.7% 9.9% 1.4 1.0-1.9 
(*): METH was identified in 14 cases only; in all of these cases, the post mortem toxicological examination identified the presence of 
amphetamine as well. Since AMP is one of the metabolites of METH [32], it is not possible to conclude from here if the 14 METH deaths 
were actually a mono-drug intoxication or just an AMP/METH combined intoxication.  
(**): There were 98 cases where both ecstasy-type drugs and amphetamines were implicated in death. 
 
 
 
 
 
 
Table 2: Overview of amphetamine/methylamphetamine- and ecstasy-associated mono-
intoxication* acute poisoning fatalities as reported to the National Programme on 
Substance Abuse Deaths - np-SAD (UK: 1997-2007) 
 Amphetamine/methylamphetamine 
(*) 106 cases 
Ecstasy (*) 
104 cases 
PR/significance 
levels 
95% CI 
Male gender  68.9%  78.8%  1.1  1.0-1.3  
Less than 34 
years at death 
55.7% 85.6% 1.6 1.3-1.9 
Age at death 
(years)  
mean  
median  
Semi-interquartile 
range  
34.2  
32.0  
8.3  
25.9  
23.9  
4.5  
Mann-Whitney  
U test= 2939,  
p <.0001 (2-
tailed) 
 
Died in hospital  44.3%  62.5%  1.4  1.1-1.8  
Known drug 
addiction 
87.8%  65.4%  2.8  1.5-5.5  
Cause of death; 
accidental  
70.8%  84.6%  1.2 1.0-1.4  
Cause of death; 
suicide  
3.8%  5.8%  1.5  0.4-5.3  
(*): Sole drug found at post mortem or sole drug implicated and no other substance found at post mortem. 
 
Table 3: Presence of contributory factors associated with either amphetamine or 
MDMA/ecstasy mono-intoxication acute poisoning – np-SAD (UK: 1997-2007) 
Amphetamine/methylamphetamine  (106 
mono-intoxication fatalities) 
Ecstasy (104 mono-intoxication 
fatalities) 
Chi-square 
values 
• 18 cases: pre-existing 
cardiovascular /cardiopulmonary issues 
(e.g.:  myocardial fibrosis; ischaemic heart 
disease; rupture of a berry aneurysm; 
cardiomyopathy; systemic hypertension; 
right ventricular dysplasia; emphysema; 
obstructive pulmonary disease; chronic 
pulmonary embolus etc) 
• 8 cases: events possibly related to 
bizarre/at-risk behaviours whilst on 
amphetamine (e.g.: 
hypothermia/immersion in water; 
drowning; multiple injuries; hanging)  
• 3 cases: associated  infections (e.g.: 
septicaemia; bronchopneumonia; acute 
meningitis) 
• 3 cases: pre-existing chronic 
medical conditions (e.g. diabetes; liver 
cirrhosis) 
 
 
In the remaining 74 (69.8%) cases, only 
amphetamines and its well-known medical 
consequences (cerebral  haemorrhage; 
multiple organ failure; acute hypertensive 
crisis etc) were mentioned as the cause of 
death 
• 8 cases: pre-existing 
cardiovascular issues (e.g.:  
cardiomegaly, coronary artery 
atherosclerosis; left ventricular 
hypertrophy, aortic valve 
incompetence; aortic aneurysm; 
dissection of aorta/Marfan's syndrome) 
• 3 cases: events possibly related 
to bizarre/at-risk behaviours whilst on 
ecstasy (e.g.: shock and haemorrhage 
due to transection of radial arteries; 
drowning; head/multiple injuries; 
physical exertion etc) 
• 1 cases: associated  infections 
(e.g.: glandular fever-Epstein Barr 
virus 
• 1 case:  possible epilepsy 
• 1 case fulminant hepatic 
failure 
 
In the remaining 90 (86.5%) cases, 
only ecstasy with its well-known acute 
medical consequences (cerebral 
oedema; hyperpyrexia; DIC/multiple 
organ failure) were mentioned as the 
cause of death 
Total number 
of 
fatalities=210; 
46 showed 
presence of 
contributory 
factors (e.g. 32 
in the 
amphetamine 
and 14 in the 
MDMA/ecstas
y group)  
Fisher's exact 
test; two-tailed 
p=0.0043 
 
  
 Table 4: Percentage of amphetamine and ecstasy deaths to all drug deaths, np-SAD data 1997-2007 
Year Amphetamine/methamphetamine 
polydrug intoxication 
Amphetamine/methamphetamine 
only 
Ecstasy 
polydrug 
intoxication 
Ecstasy 
only 
1997 5.50 0.95 1.14 0.19 
1998 6.23 0.87 1.23 0.29 
1999 5.48 0.65 2.22 0.26 
2000 3.02 0.26 3.08 0.46 
2001 3.59 0.51 4.32 0.79 
2002 4.47 0.28 3.80 0.55 
2003 5.19 0.60 3.46 0.30 
2004 3.49 0.44 3.54 0.98 
2005 4.30 0.96 3.54 0.71 
2006 4.68 0.58 3.90 0.73 
2007 5.00 0.58 3.61 0.48 
Average 
1997-2007 4.53 0.58 3.29 0.57 
All cases on np-SAD database 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5: Rates of deaths per 100,000 users for amphetamine and ecstasy, including multiple drug use 
(England and Wales; 2001-2007)  (#) 
 Year  Amphetamine/methamphetamine;  
young people (16-24) * 
Ecstasy; 
young 
people 
(16-24) * 
Amphetamine/methamphetamine; 
all persons (16-59) 
Ecstasy;  
All 
persons 
(16-59) 
2001 6.03 8.07 12.80 10.44 
2002 5.56 6.09 16.46 10.60 
2003 7.63 6.01 16.98 9.12 
2004 8.37 7.14 16.05 10.61 
2005 6.34 5.58 18.31 12.75 
2006 7.73 5.88 19.95 10.93 
2007 6.49 7.14 27.96 12.55 
Average 
2001-7 
6.85 6.62 17.87 10.89 
Standard 
Deviation 
1.04 0.91 4.77 1.27 
t-test  t-value of 
difference: 
1.793; df-
t: 202 
double-
sided p-
value: 
0.0748 
 t-value of 
difference: 
32.824; 
df-t: 642 
double-
sided p-
value: 0 
*: only 16-24 years old cases were here taken into account  
#: Sources:  
Death rates: np-SAD datafile – England & Wales cases only 
Users’ rates:   
2001/2 – Findings 182 
2002/3 – Findings 229  
2003/4 – Statistical Bulletin 04/05 
2004/5 – Statistical Bulletin 16/05 
2005/6 – Statistical Bulletin 15/06 
2006/7 – Statistical Bulletin 18/07 
2007/8 – Statistical Bulletin 13/08 
 
 
 
 
 
Table 6: Rates of deaths per 100,000 users for amphetamine and ecstasy, sole drug use (England and 
Wales; 2001-2007) 
 Year  Amphetamines 
Young people (16-
24) * 
Ecstasy  Young 
people (16-24) * 
Amphetamines All 
persons (16-59) 
Ecstasy  All 
persons (16-
59) 
2001 0.35 2.60 1.83 1.76 
2002 0.46 1.28 1.03 1.47 
2003 1.27 0.95 2.07 0.81 
2004 0.99 1.70 1.86 2.16 
2005 0.98 1.49 3.76 2.59 
2006 0.00 1.84 1.66 1.94 
2007 1.95 1.59 2.74 1.70 
Average 
2001-7 
0.80 1.67 2.09 1.75 
Standard 
Deviation 
0.65 0.52 0.88 0.56 
t-test  t-value of 
difference: -
4.199; df-t: 16 
double-sided p-
value: 0.0007 
 t-value of 
difference: 
2.641; df-t: 
105 
double-sided 
p-value: 
0.0096 
*: only 16-24 years old cases were here taken into account  
#: Sources:  
Death rates: np-SAD datafile – England & Wales cases only 
Users’ rates:   
2001/2 – Findings 182 
2002/3 – Findings 229  
2003/4 – Statistical Bulletin 04/05 
2004/5 – Statistical Bulletin 16/05 
2005/6 – Statistical Bulletin 15/06 
2006/7 – Statistical Bulletin 18/07 
2007/8 – Statistical Bulletin 13/08 
 
 
 
 
 
 
 
 
 Figure 1: Number of amphetamine/methylamphetamine and 
MDMA/ecstasy deaths reported to np-SAD, 1997-2007
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 Figure 2: Percentage of amphetamine and ecstasy deaths to all 
deaths, np-SAD 1997-2007
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Figure 3: Rate of deaths per 100,000 users aged 16-
59, England & Wales (np-SAD and BCS data), 2001-7
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Figure 4: Rate of deaths per 100,000 users aged 16-24, 
England & Wales (np-SAD and BCS data), 2001-7
0
2
4
6
8
10
2001 2002 2003 2004 2005 2006 2007
Year of death
R
a
te
Amphetamine polydrug Amphetamine
Ecstasy polydrug Ecstasy
 
 
 
